Azvudine for new hepatitis B patients
Part of Digestive system, Infections clinical trials.
This study tests a new pill (azvudine) to see if it can cure chronic hepatitis B in people who have never been treated before. It is for those with active infection and elevated liver enzymes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had hepatitis B with a positive surface antigen (HBsAg) and e antigen (HBeAg) for at least 6 months.
- Your HBV DNA (virus level) must be above 20,000 copies/mL, and your HBsAg below 1,500 IU/mL.
- Your ALT (a liver enzyme) must be more than twice the normal upper limit.
- You cannot have taken any antiviral medication for hepatitis B before.
- You cannot have any other liver infections (like hepatitis A, C, D, or E) or HIV.
- You cannot be pregnant, breastfeeding, or planning pregnancy within the next year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called ZM-H1505R added to your current daily oral antiviral to see if it can better control hepatitis B virus. It's for people whose virus is still active despite standard treatment.
This trial tests a new medicine (VIR-2218) combined with a standard injection (peginterferon) to see if it can better control chronic hepatitis B. It may be an option if your virus levels are low and you haven't had recent treatment.
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.